Irinotecano Kabi (Irinotecan Hydrochloride Trihydrate)

Irinotecan is used in oncology to target cancers that rely on rapid DNA replication.

• Colorectal cancer: improves survival when combined with standard chemotherapy regimens.
• Metastatic colorectal cancer: provides disease control in patients with advanced disease.
• Adjuvant therapy for colon cancer: reduces risk of recurrence after surgical resection.

• Irinotecan is a prodrug converted to SN‑38, which binds to the DNA‑topoisomerase I complex and stabilizes it, preventing the relegation of single‑strand DNA breaks. This inhibition blocks DNA unwinding during replication, leading to accumulation of DNA damage and ultimately tumor cell death.

Irinotecan may cause a range of adverse reactions, from mild to severe.

Common Side Effects

• Nausea and vomiting: gastrointestinal upset commonly reported during treatment.
• Diarrhea: may be severe and require supportive care.
• Neutropenia: reduced white blood cell count increasing infection risk.
• Alopecia: temporary hair loss during therapy.
• Fatigue: generalized tiredness affecting daily activities.
• Anemia: decreased red blood cell count causing weakness.

Serious or Rare Side Effects

• Severe neutropenic infection: life‑threatening bacterial or fungal infections.
• Febrile neutropenia: fever accompanying low neutrophil counts.
• Acute cholinergic syndrome: abdominal cramping, sweating, and bradycardia.
• Severe allergic reactions: anaphylaxis or hypersensitivity.
• Hepatotoxicity: elevated liver enzymes indicating liver injury.
• Cardiac toxicity: rare cases of arrhythmia or myocardial ischemia.

Before initiating Irinotecano Kabi, clinicians should assess patient suitability and monitor for potential complications.

• Baseline blood counts: obtain complete blood count to detect pre‑existing cytopenias.
• Liver function: evaluate hepatic enzymes as metabolism occurs hepatically.
• Renal function: assess creatinine clearance for dose adjustment considerations.
• Concomitant medications: review for agents that may increase toxicity, such as other myelosuppressive drugs.
• Pregnancy and lactation: avoid use unless benefits clearly outweigh risks.
• Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Irinotecan can interact with several drugs that affect its metabolism or toxicity profile.

Major Interactions (Avoid)

• Strong CYP3A4 inducers (e.g., rifampin): may reduce efficacy by increasing clearance.
• Anticholinesterase agents (e.g., neostigmine): can exacerbate cholinergic syndrome.
• High‑dose corticosteroids: may increase risk of neutropenia.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inhibitors (e.g., fluconazole): may raise plasma levels.
• Warfarin: monitor INR as bleeding risk may increase.
• Other myelosuppressive chemotherapy: heightened bone‑marrow suppression.
• Proton pump inhibitors: potential effect on gastric pH and absorption of oral formulations (if applicable).